Literature DB >> 28284258

Mycobacterium tuberculosis infection among persons who inject drugs in San Diego, California.

R F Armenta1, K M Collins2, S A Strathdee2, M A Bulterys2, F Munoz2, J Cuevas-Mota2, P Chiles3, R S Garfein2.   

Abstract

BACKGROUND: Persons who inject drugs (PWID) might be at increased risk for Mycobacterium tuberculosis infection and reactivation of latent tuberculous infection (LTBI) due to their injection drug use.
OBJECTIVES: To determine prevalence and correlates of M. tuberculosis infection among PWID in San Diego, California, USA.
METHODS: PWID aged 18 years underwent standardized interviews and serologic testing using an interferon-gamma release assay (IGRA) for LTBI and rapid point-of-care assays for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Independent correlates of M. tuberculosis infection were identified using multivariable log-binomial regression.
RESULTS: A total of 500 participants met the eligibility criteria. The mean age was 43.2 years (standard deviation 11.6); most subjects were White (52%) or Hispanic (30.8%), and male (75%). Overall, 86.7% reported having ever traveled to Mexico. Prevalence of M. tuberculosis infection was 23.6%; 0.8% were co-infected with HIV and 81.7% were co-infected with HCV. Almost all participants (95%) had been previously tested for M. tuberculosis; 7.6% had been previously told they were infected. M. tuberculosis infection was independently associated with being Hispanic, having longer injection histories, testing HCV-positive, and correctly reporting that people with 'sleeping' TB cannot infect others.
CONCLUSIONS: Strategies are needed to increase awareness about and treatment for M. tuberculosis infection among PWID in the US/Mexico border region.

Entities:  

Mesh:

Year:  2017        PMID: 28284258      PMCID: PMC6352726          DOI: 10.5588/ijtld.16.0434

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  26 in total

1.  Mycobacterium tuberculosis and human immunodeficiency virus co-infection in intravenous drug users on admission to prison.

Authors:  V Martín; J A Caylà; A Bolea; J Castilla
Journal:  Int J Tuberc Lung Dis       Date:  2000-01       Impact factor: 2.373

2.  Reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Sharon Perry; Luz Sanchez; Shufang Yang; Zubin Agarwal; Philip Hurst; Julie Parsonnet
Journal:  Clin Vaccine Immunol       Date:  2008-01-16

3.  Tuberculin skin testing in intravenous drug users: differences between HIV-seropositive and HIV-seronegative subjects.

Authors:  José J Portu; Mikel Aldamiz-Etxebarria; José M Agud; José M Arévalo; María J Almaraz; Cándido Ayensa
Journal:  Addict Biol       Date:  2002-04       Impact factor: 4.280

4.  Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto.

Authors:  I D Rusen; L Yuan; M E Millson
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

Review 5.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa.

Authors:  Y D Mukadi; D Maher; A Harries
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

6.  Tuberculosis along the United States-Mexico border, 1993-2001.

Authors:  Eileen Schneider; Kayla F Laserson; Charles D Wells; Marisa Moore
Journal:  Rev Panam Salud Publica       Date:  2004-07

Review 7.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

8.  High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico.

Authors:  R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee
Journal:  Int J Tuberc Lung Dis       Date:  2009-05       Impact factor: 2.373

9.  Yield of tuberculin screening among injection drug users.

Authors:  P Brassard; J Bruneau; K Schwartzman; M Sénécal; D Menzies
Journal:  Int J Tuberc Lung Dis       Date:  2004-08       Impact factor: 2.373

10.  T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data.

Authors:  Anandharaman Veerapathran; Rajnish Joshi; Kalyan Goswami; Sandeep Dogra; Erica E M Moodie; M V R Reddy; Shriprakash Kalantri; Kevin Schwartzman; Marcel A Behr; Dick Menzies; Madhukar Pai
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

View more
  4 in total

1.  Changing Spectrum of Opportunistic Illnesses among HIV-Infected Taiwanese Patients in Response to a 10-Year National Anti-TB Programme.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Po-Liang Lu; Hung-Chin Tsai
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

2.  Testing for Drug-Related Infectious Diseases and Determinants among People Who Use Drugs in a Low-Resource Setting: A Respondent-Driven Cross-Sectional Survey.

Authors:  Samuel Lazarus Likindikoki; Elia J Mmbaga; Mucho Mizinduko; Mwijage Alexander; Lisa V Adams; Robert Horsburgh; Kåre Moen; Germana Leyna; Theis Lange; Britt P Tersbøl; Melkizedeck Leshabari; Dan W Meyrowitsch
Journal:  Trop Med Infect Dis       Date:  2022-08-29

3.  Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks.

Authors:  Tetyana I Vasylyeva; Pavlo Smyrnov; Steffanie Strathdee; Samuel R Friedman
Journal:  J Int AIDS Soc       Date:  2020-07       Impact factor: 5.396

4.  Prevalence and correlates of obstructive lung disease among people who inject drugs, San Diego, California.

Authors:  Hayley J Koslik; Jisha Joshua; Jazmine Cuevas-Mota; Daniel Goba; Eyal Oren; John E Alcaraz; Richard S Garfein
Journal:  Drug Alcohol Depend       Date:  2020-07-02       Impact factor: 4.492

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.